Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Part of paid clinical trials in Rochester, New York.
- Sponsor
- University of Rochester
- Study ID
- NCT03463408
- Phase
- EARLY_PHASE1
- Status
- Active Not Recruiting
Conditions
- Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- nivolumab — DRUG240 mg every 2 weeks
- ipilimumab — DRUG1 mg/kg every 6 weeks
Study Details
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Key Dates
- Start date
- Jul 17, 2018
- Status verified
- Jul 2025
- Primary completion
- Aug 1, 2026
- Completion
- Aug 1, 2026
Study Design
- Enrollment
- 14 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Immunotherapy armCohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses). Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment.
- No Intervention: no immunotherapy armCohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group. Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment.
Primary Outcome Measure
Adverse Event evaluation [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York | 14642-0001 | - |
Find similar trials in Rochester, NY
Related Studies
- Novel Biochemical and Molecular Determinants for Soft Tissue SarcomaRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesRecruiting · National Cancer Institute (NCI) · Washington D.C., District of Columbia
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaPHASE1/PHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · St. Petersburg, Florida